Faron Pharmaceuticals Oy Share Discussion Threads

[dan1nat1] 19/9/2018 22:16

With our limited free float good news could see us flying!

[sampsun] 19/9/2018 19:55

Does anyone else feel this could have a fantastic jump on good news?

[jobber1] 18/9/2018 12:17

B1tcoin,

Any comment today, or have you gone completely?

[dave4545] 18/9/2018 10:05

1000 max online at 108p so a few getting involved again

[dave4545] 18/9/2018 09:53

Might have a mini spike on the back of that "insider trading" rns so took some at 106p

[dave4545] 18/9/2018 09:32

"On 17 September 2018, a person closely associated with Dr. Matti Karvonen, Chief Medical Officer of Faron, had acquired 4,414 ordinary shares in Faron at a price of 100 pence per ordinary share"

[jnbrw] 17/9/2018 13:59

No

The Japanese results are unknown ( although my view is they may be complicated and inconclusive for many of the same reasons the European pIII trial did not meet its endpoint).

Regulatory hurdles are (rightly) quite high for any new drugs.I would be most surprised if the drug was approved for use in Japan when European and American regulators require further trials due to previous trials having failed. Regulators usually err on the side of caution.

[dan1nat1] 17/9/2018 12:07

And if the Japanese p3 trial is a success due to using data from the euro p3, we can initially move to market in that region only...or do you also take from the interview that that has failed?

[jnbrw] 16/9/2018 22:24

I have rewatched the interview and the guy from the co clearly states the findings from the investigations into the p III ards trial failure will be worked into and used in the setting up of the new trials of traumakine if they go ahead.

Confirmation that any commercialisation of any new products (if any of the trials are ultimately successful) are AT BEST 18 months to 2 or 3 years away.

They will need a new working capital fundraising round long before then.

And P II and PIII trials of any drugs that emerge as candidates will also need fund raising.

[daa1] 16/9/2018 14:32

Faron has made a major update to their pipeline on their website on 13th of September 2018.

There are several new diseases mentioned in the pipeline.

Interestingly there is also under Traumakine a Global, ARDS trial. The same goes for D-ARDS. I don't remember these being there before, so I checked what the pipeline used to be before from Wayback machine. They have a snapshot from the pipeline from 25th of August 2017 and at that time there wasn't a Global ARDS trial.

[inv] 14/9/2018 07:59

massively oversold

[dan1nat1] 13/9/2018 22:11

Agreed the strategy will be different now, but until the 22nd of October please don't try to mislead people into believing you know what it will be.Based on the original strategy we had a market cap around £240m, it's now around £30m some might say we have been significantly oversold based on the positive outlook of the latest interview.

[jnbrw] 13/9/2018 20:21

Dan NAT - by material I meant in terms of commercialisation ( producing and selling the drug ) which was the original strategy and what the mkt was planning for. Don't mislead others and yourself the European PIII trial failure will mean another phase three trial at best.This will cost and take years, however much people want to put a positive slant on it.

[dan1nat1] 13/9/2018 17:15

hxxp://www.proactiveinvestors./companies/stocktube/10466/faron-pharma-to-take-clevegen-cancer-candidate-into-the-clinic-this-year-10466.html

add .co.uk to get the link

[dan1nat1] 13/9/2018 17:14

No sure we watched the same interview, as you didn't post the link for some reason? -

[...]

Traumakine - full update 22nd Oct, not sure what you can possibly be basing "nothing material happening soon" on? He actually seemed very positive on the future of Traumakine, and I consider 22nd Oct to be pretty soon.

Clevegen looks to be a fantastic prospect, with potential to be used as more than just a cancer treatment. Funding will be needed, but certainly not before we are updated on Traumakine and hopfully re-rated back to were we should be.

I suggests everybody watches the video and makes there own mind up.

[jnbrw] 13/9/2018 16:59

Just watched the interview and just confirms what I thought this am.

Nothing material will happen with traumakine soon, water has been muddied too much now to hope for any sort of approvals granted imo and certainly no income from this side anytime soon ( as some have claimed).

Clevegen may be a good prospect but it is going to need a lot of funds and several years to get it through the layers of trials it needs before it gets to the market.

I expect funds will need to be raised in the coming months as funding requirements are not advantageous when left to the last minute.

[jnbrw] 13/9/2018 09:26

It does look increasingly like co are pushing clevegen to the fore and sidelining traumakine or at least downplaying its importance ( without actually saying as much).I reckon traumakine will limp on with a new " strategy" with an inconclusive Japan result and clevegen will be main focus going forward.

Progressing Clevegen will need another load of fundraising to get through P II and III trials ( if successful up to that point) So ultimately, fundraising/dilution on the way imo.

[latifs100] 13/9/2018 08:38

only 10 million cash left, looks like vernalis, (sold for 6p)

[dan1nat1] 13/9/2018 08:38

Holding £1 will be key. I closed my trading position on open at 110, have now reopened at 102. My Isa holdings are long term and are waiting for a minimum extra zero.

[jnbrw] 13/9/2018 07:51

Quite disappointed after such a long wait to hear about traumakine strategy. No new info about the P3 trial failure, Japanese trial outcome delayed and a wait til Oct now for info on the strategy going forward?

[dan1nat1] 12/9/2018 22:41

Yes if it's on time three weeks left. With no nasty surprises tomorrow we could easily run up to £2 before results are announced. Then from that base on good results a serious re-rate from current levels is well on the cards. We will get that bitcoin rally yet ;)